Clinical Trial Update: Docetaxel and Lapatinib in Metastatic Transitional Cell Carcinoma in Bladder [Phase 2]

View source ↗

Summary

Phase 2 trial of docetaxel in combination with lapatinib for metastatic transitional cell carcinoma of the bladder was terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Bladder

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Lapatinib (Lapatinib)

Snippet

Sponsor: University of Southern California | Conditions: Recurrent Bladder Cancer, Stage III Bladder Cancer | Phase 2 | Status: TERMINATED | Results posted: 2025-10-09